132 related articles for article (PubMed ID: 33603145)
1. Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands.
Ector GICG; Visser O; Posthuma EFM; Westerweel PE; Janssen JJWM; Blijlevens NMA; Dinmohamed AG
Leukemia; 2021 Nov; 35(11):3291-3294. PubMed ID: 33603145
[No Abstract] [Full Text] [Related]
2. Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival.
Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Willemsen SP; Valk PJM; Visser O; Cornelissen JJ; Westerweel PE
Haematologica; 2017 Dec; 102(12):e486-e489. PubMed ID: 28860340
[No Abstract] [Full Text] [Related]
3. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Wang W; Cortes JE; Liu E; Miranda RN; Zhao C; Yuan J; Lu X; Yang W; Ameri MD; Kantarjian HM; Medeiros LJ; Hu S
Blood Cancer J; 2016 May; 6(5):e418. PubMed ID: 27152845
[No Abstract] [Full Text] [Related]
4. CML - we are not there yet.
Hehlmann R
Eur J Haematol; 2016 Aug; 97(2):107. PubMed ID: 26643149
[No Abstract] [Full Text] [Related]
5. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.
Maas CCHM; van Klaveren D; Ector GICG; Posthuma EFM; Visser O; Westerweel PE; Janssen JJWM; Blijlevens NMA; Dinmohamed AG
Br J Haematol; 2022 Mar; 196(5):1219-1224. PubMed ID: 34865221
[TBL] [Abstract][Full Text] [Related]
6. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
Sasaki K; Kantarjian HM; Jain P; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Takahashi K; Pemmaraju N; Daver N; Pierce SA; O'Brien SM; Cortes JE
Cancer; 2016 Jan; 122(2):238-48. PubMed ID: 26479889
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
Höglund M; Sandin F; Hellström K; Björeman M; Björkholm M; Brune M; Dreimane A; Ekblom M; Lehmann S; Ljungman P; Malm C; Markevärn B; Myhr-Eriksson K; Ohm L; Olsson-Strömberg U; Själander A; Wadenvik H; Simonsson B; Stenke L; Richter J
Blood; 2013 Aug; 122(7):1284-92. PubMed ID: 23843494
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Pagnano KB; Bendit I; Boquimpani C; De Souza CA; Miranda EC; Zalcberg I; Larripa I; Nardinelli L; Silveira RA; Fogliatto L; Spector N; Funke V; Pasquini R; Hungria V; Chiattone CS; Clementino N; Conchon M; Moiraghi EB; Lopez JL; Pavlovsky C; Pavlovsky MA; Cervera EE; Meillon LA; Simões B; Hamerschlak N; Bozzano AH; Mayta E; Cortes J; Bengió RM;
Cancer Invest; 2015; 33(9):451-8. PubMed ID: 26288116
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012.
Thielen N; Visser O; Ossenkoppele G; Janssen J
Eur J Haematol; 2016 Aug; 97(2):145-54. PubMed ID: 26519944
[TBL] [Abstract][Full Text] [Related]
10. Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population-based study.
Jamy O; Godby R; Sarmad R; Costa LJ
Am J Hematol; 2021 Jul; 96(7):E265-E268. PubMed ID: 33864684
[No Abstract] [Full Text] [Related]
11. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
[TBL] [Abstract][Full Text] [Related]
12. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
[TBL] [Abstract][Full Text] [Related]
13. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Cortes JE; Jorgensen JL; Wang W; Yin CC; You MJ; Jabbour E; Kantarjian HM; Medeiros LJ; Hu S
Leukemia; 2016 Jul; 30(7):1606-9. PubMed ID: 26837843
[No Abstract] [Full Text] [Related]
14. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
15. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
16. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
Zhang XS; Gale RP; Huang XJ; Jiang Q
Leukemia; 2022 Feb; 36(2):482-491. PubMed ID: 34413457
[TBL] [Abstract][Full Text] [Related]
17. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.
Wang W; Cortes JE; Lin P; Khoury JD; Ai D; Tang Z; Tang G; Jorgensen JL; Medeiros LJ; Hu S
Leukemia; 2015 Nov; 29(11):2263-6. PubMed ID: 25931274
[No Abstract] [Full Text] [Related]
18. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
19. Patients' perspectives on the definition of cure in chronic myeloid leukemia.
Flynn KE; Mauro MJ; George G; Hinman A; Baim A; Kota V; Larson RA; Lipton JH; Thompson JE; Wadleigh M; Atallah E
Leuk Res; 2019 May; 80():40-42. PubMed ID: 30955853
[No Abstract] [Full Text] [Related]
20. The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors.
Chien SH; Liu HM; Chen PM; Ko PS; Lin JS; Chen YJ; Lee LH; Hsiao LT; Chiou TJ; Gau JP; Yang MH; Liu CY
Hematol Oncol; 2020 Aug; 38(3):390-398. PubMed ID: 32011024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
